7-Hydroxystaurosporine

Generic Name: 7-Hydroxystaurosporine

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₆N_₄O_₄

CAS Number: 112953-11-4

Unique Ingredient Identifier: 7BU5H4V94A

Clinical Trials

7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: 7-hydroxystaurosporine
Drug: cisplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00012194

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: carboplatin
Drug: 7-hydroxystaurosporine
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00036777

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States

UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00045747

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Phase 1

Completed

Conditions: Advanced Adult Primary Liver Cancer
Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Recurrent Gastric Cancer
Recurrent Gastrointestinal Carcinoid Tumor
Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
Carcinoma of the Appendix
Gastrointestinal Stromal Tumor
Estrogen Receptor-negative Breast Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: irinotecan hydrochloride
Other: diagnostic laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00031681

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2015-07-23

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT00045513

Locations: 🇨🇦
Princess Margaret Hospital at University Health Network, Toronto, Ontario, Canada
🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
London Health Sciences Centre, London, Ontario, Canada

UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2010-08-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT00047242

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00042861

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Phase 1

Completed

Conditions: Lymphoma
Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019838

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00045500

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Frederick Cancer Research and Development Center, Frederick, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 33

Registration Number: NCT00045175

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy